DB
SRPT icon

Dmitry Balyasny’s Sarepta Therapeutics SRPT Stock Holding History

Dmitry Balyasny’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Buy
100,000
+25,000
+33% +$473K ﹤0.01% 1878
2026
Q1 		$1.63M Sell
75,000
-75,000
-50% -$1.45M ﹤0.01% 1874
2025
Q4 		$3.23M Sell
150,000
-233,000
-61% -$4.91M ﹤0.01% 1629
2025
Q3 		$7.38M Buy
383,000
+93,000
+32% +$1.66M 0.01% 1198
2025
Q2 		$4.96M Buy
+290,000
New +$12.4M 0.01% 1299
2024
Q1 		– Sell
-43,800
Closed -$4.22M – 3094
2023
Q4 		$4.22M Sell
43,800
-91,600
-68% -$8.79M 0.01% 1179
2023
Q3 		$16.4M Hold
135,400
– – 0.03% 651
2023
Q2 		$15.5M Sell
135,400
-110,000
-45% -$14.2M 0.03% 616
2023
Q1 		$33.8M Sell
245,400
-163,700
-40% -$21.2M 0.08% 334
2022
Q4 		$53M Buy
409,100
+29,500
+8% +$3.42M 0.15% 178
2022
Q3 		$42M Buy
379,600
+100,800
+36% +$10.2M 0.13% 191
2022
Q2 		$20.9M Buy
278,800
+112,700
+68% +$8.29M 0.07% 410
2022
Q1 		$13M Buy
166,100
+122,100
+278% +$9.35M 0.04% 592
2021
Q4 		$3.96M Sell
44,000
-18,000
-29% -$1.54M 0.01% 921
2021
Q3 		$5.73M Buy
+62,000
New +$4.78M 0.02% 772

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dmitry Balyasny's SRPT Position: Q2 2026 in Review

Dmitry Balyasny reduced its Sarepta Therapeutics (SRPT) stake by 61% in Q2 2026, selling an estimated $4.53M and leaving 152,280 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1662.

Dmitry Balyasny first reported a position in SRPT in Q2 2013 and has held it in 34 quarters since. The position peaked at $84.2M in Q2 2024. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Dmitry Balyasny held 152,280 shares of Sarepta Therapeutics worth $2.74M as of Q2 2026.
  • Dmitry Balyasny sold 239,764 Sarepta Therapeutics shares in Q2 2026, an estimated $4.53M.
  • Sarepta Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1662 holding.
  • Dmitry Balyasny first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 34 quarters since.
  • Dmitry Balyasny's Sarepta Therapeutics position peaked at $84.2M in Q2 2024.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.